Your browser doesn't support javascript.
loading
The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma.
Wang, Shiyan; Zeng, Yong; Zhu, Lin; Zhang, Min; Zhou, Lei; Yang, Weixiong; Luo, Weishan; Wang, Lina; Liu, Yanming; Zhu, Helen; Xu, Xin; Su, Peiran; Zhang, Xinyue; Ahmed, Musaddeque; Chen, Wei; Chen, Moliang; Chen, Sujun; Slobodyanyuk, Mykhaylo; Xie, Zhongpeng; Guan, Jiansheng; Zhang, Wen; Khan, Aafaque A; Sakashita, Shingo; Liu, Ni; Pham, Nhu-An; Boutros, Paul C; Ke, Zunfu; Moran, Michael F; Cai, Zongwei; Cheng, Chao; Yu, Jun; Tsao, Ming Sound; He, Housheng Hansen.
Afiliación
  • Wang S; Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Zeng Y; University Health Network, Canada.
  • Zhu L; Hong Kong Baptist University, Hong Kong, Hong Kong.
  • Zhang M; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Zhou L; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Yang W; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Luo W; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Wang L; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Liu Y; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Zhu H; University of Toronto, Toronto, Ontario, Canada.
  • Xu X; Princess Margaret Cancer Centre, Toronto, Ontario,, Canada.
  • Su P; Princess Margaret Cancer Centre, Canada.
  • Zhang X; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Ahmed M; Princess Margaret Cancer Center/University Health Network, Toronto, Canada, United States.
  • Chen W; Department of Respiratory and Critical Care Medicine, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, huaian, China.
  • Chen M; Princess Margaret Cancer Centre, Toronto, Ontario,, Canada.
  • Chen S; Princess Margaret Cancer Centre, Toronto, Ontario,, Canada.
  • Slobodyanyuk M; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Xie Z; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guan J; Princess Margaret Cancer Centre, Toronto, Ontario,, Canada.
  • Zhang W; Lundbeck Seattle BioPharmaceuticals, Bothell, WA, United States.
  • Khan AA; Institute of Bioinformatics, Bangalore, Karnataka, India.
  • Sakashita S; National Cancer Center Hospital East, kashiwa, Chiba, Japan.
  • Liu N; University Health Network, Toronto, Ontario, Canada.
  • Pham NA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Boutros PC; University of California, Los Angeles, Los Angeles, California, United States.
  • Ke Z; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Moran MF; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Cai Z; Hong Kong Baptist University, Hong Kong, China.
  • Cheng C; First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Yu J; Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Tsao MS; University of Toronto, Toronto, Ontario, Canada.
  • He HH; Princess Margaret Cancer Centre, Toronto, Ontario,, Canada.
Cancer Discov ; 2024 Jun 25.
Article en En | MEDLINE | ID: mdl-38922581
ABSTRACT
Comprehensive m6A epitranscriptome profiling of primary tumors remains largely uncharted. Here, we profiled the m6A epitranscriptome of 10 non-neoplastic lung (NL) tissues and 51 lung adenocarcinoma (LUAD) tumors, integrating the corresponding transcriptome, proteome and extensive clinical annotations. We identified distinct clusters and genes that were exclusively linked to disease progression through m6A modifications. In comparison with NL tissues, we identified 430 transcripts to be hypo-methylated and 222 to be hyper-methylated in tumors. Among these genes, EML4 emerged as a novel metastatic driver, displaying significant hyper-methylation in tumors. m6A modification promoted the translation of EML4, leading to its widespread overexpression in primary tumors. Functionally, EML4 modulated cytoskeleton dynamics through interacting with ARPC1A, enhancing lamellipodia formation, cellular motility, local invasion, and metastasis. Clinically, high EML4 protein abundance correlated with features of metastasis. METTL3 small molecule inhibitor markedly diminished both EML4 m6A and protein abundance, and efficiently suppressed lung metastases in vivo.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Discov Año: 2024 Tipo del documento: Article País de afiliación: Hong Kong

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Discov Año: 2024 Tipo del documento: Article País de afiliación: Hong Kong
...